Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):319–326. doi: 10.1038/bjc.1993.335

Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.

M Samadi-Baboli 1, G Favre 1, P Canal 1, G Soula 1
PMCID: PMC1968583  PMID: 8347487

Abstract

Significant low density lipoprotein (LDL) uptake by tumour cells led to the use of LDL as a discriminatory vehicle for the delivery of cytotoxic drugs. In the current study, the lipophilic elliptinium derivative, elliptinium-oleate (OL-NME), was incorporated into LDL to reach an incorporation level of 400 molecules per LDL particle. The OL-NME-LDL complex showed cytotoxic effects on normal human fibroblasts while the cytotoxicity was not observed on receptor-defective human fibroblasts, indicating the ability of the complex to be preferentially metabolised by the LDL receptor. In vivo metabolism of the complex was related to the LDL receptor pathway. The metabolic clearance was the same for native LDL (17.1 ml h-1) and OL-NME-LDL complex (16.2 ml h-1). LDL incorporated OL-NME enhanced the anti-tumour activity against murine B16 melanoma model; this resulted from increased efficacy for OL-NME-LDL at doses equal to free 9-OH-NME (157 vs 76 of Increase Life Span (ILS) (%) values after intraperitoneal (i.p.) drug injection on i.p. implanted tumour model and 45 vs -2 ILS (%) values after intravenous drug injection on subcutaneous implanted tumour model). These data suggest that LDL improves the potency of lipophilic cytotoxic drugs against tumours that express LDL receptor activity.

Full text

PDF
320

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auclair C., Pierre A., Voisin E., Pepin O., Cros S., Colas C., Saucier J. M., Verschuere B., Gros P., Paoletti C. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl. Cancer Res. 1987 Dec 1;47(23):6254–6261. [PubMed] [Google Scholar]
  2. Aviram M., Bierman E. L., Chait A. Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem. 1988 Oct 25;263(30):15416–15422. [PubMed] [Google Scholar]
  3. Bilheimer D. W., Eisenberg S., Levy R. I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972 Feb 21;260(2):212–221. doi: 10.1016/0005-2760(72)90034-3. [DOI] [PubMed] [Google Scholar]
  4. Brown M. S., Goldstein J. L. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986 Apr 4;232(4746):34–47. doi: 10.1126/science.3513311. [DOI] [PubMed] [Google Scholar]
  5. Chait A., Eisenberg S., Steinmetz A., Albers J. J., Bierman E. L. Low-density lipoproteins modified by lipid transfer protein have altered biological activity. Biochim Biophys Acta. 1984 Sep 12;795(2):314–325. doi: 10.1016/0005-2760(84)90081-x. [DOI] [PubMed] [Google Scholar]
  6. Dullaart R. P., Groener J. E., Erkelens D. W. Effect of the composition of very low and low density lipoproteins on the rate of cholesterylester transfer from high density lipoproteins in man, studied in vitro. Eur J Clin Invest. 1987 Jun;17(3):241–248. doi: 10.1111/j.1365-2362.1987.tb01243.x. [DOI] [PubMed] [Google Scholar]
  7. Eisenberg S. Preferential enrichment of large-sized very low density lipoprotein populations with transferred cholesteryl esters. J Lipid Res. 1985 Apr;26(4):487–494. [PubMed] [Google Scholar]
  8. Gal D., Ohashi M., MacDonald P. C., Buchsbaum H. J., Simpson E. R. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol. 1981 Apr 15;139(8):877–885. doi: 10.1016/0002-9378(81)90952-2. [DOI] [PubMed] [Google Scholar]
  9. Goldstein J. L., Brown M. S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974 Aug 25;249(16):5153–5162. [PubMed] [Google Scholar]
  10. Goldstein J. L., Brown M. S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897–930. doi: 10.1146/annurev.bi.46.070177.004341. [DOI] [PubMed] [Google Scholar]
  11. Gotto A. M., Jr, Pownall H. J., Havel R. J. Introduction to the plasma lipoproteins. Methods Enzymol. 1986;128:3–41. doi: 10.1016/0076-6879(86)28061-1. [DOI] [PubMed] [Google Scholar]
  12. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hynds S. A., Welsh J., Stewart J. M., Jack A., Soukop M., McArdle C. S., Calman K. C., Packard C. J., Shepherd J. Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim Biophys Acta. 1984 Oct 4;795(3):589–595. doi: 10.1016/0005-2760(84)90189-9. [DOI] [PubMed] [Google Scholar]
  14. Iwanik M. J., Shaw K. V., Ledwith B. J., Yanovich S., Shaw J. M. Preparation and interaction of a low-density lipoprotein:daunomycin complex with P388 leukemic cells. Cancer Res. 1984 Mar;44(3):1206–1215. [PubMed] [Google Scholar]
  15. Kleinman Y., Schonfeld G., Gavish D., Oschry Y., Eisenberg S. Hypolipidemic therapy modulates expression of apolipoprotein B epitopes on low density lipoproteins. Studies in mild to moderate hypertriglyceridemic patients. J Lipid Res. 1987 May;28(5):540–548. [PubMed] [Google Scholar]
  16. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 1990 Feb 8;343(6258):531–535. doi: 10.1038/343531a0. [DOI] [PubMed] [Google Scholar]
  17. Krieger M., Smith L. C., Anderson R. G., Goldstein J. L., Kao Y. J., Pownall H. J., Gotto A. M., Jr, Brown M. S. Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. J Supramol Struct. 1979;10(4):467–478. doi: 10.1002/jss.400100409. [DOI] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Lestavel-Delattre S., Martin-Nizard F., Clavey V., Testard P., Favre G., Doualin G., Houssaini H. S., Bard J. M., Duriez P., Delbart C. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res. 1992 Jul 1;52(13):3629–3635. [PubMed] [Google Scholar]
  20. Lombardi P., Norata G., Maggi F. M., Canti G., Franco P., Nicolin A., Catapano A. L. Assimilation of LDL by experimental tumours in mice. Biochim Biophys Acta. 1989 Jun 28;1003(3):301–306. doi: 10.1016/0005-2760(89)90236-1. [DOI] [PubMed] [Google Scholar]
  21. Mahley R. W., Innerarity T. L., Pitas R. E., Weisgraber K. H., Brown J. H., Gross E. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem. 1977 Oct 25;252(20):7279–7287. [PubMed] [Google Scholar]
  22. Masquelier M., Vitols S., Peterson C. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res. 1986 Aug;46(8):3842–3847. [PubMed] [Google Scholar]
  23. Mayer L. D., Bally M. B., Loughrey H., Masin D., Cullis P. R. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 1990 Feb 1;50(3):575–579. [PubMed] [Google Scholar]
  24. Mazzone T., Basheeruddin K., Ping L., Schick C. Relation of growth- and sterol-related regulatory pathways for low density lipoprotein receptor gene expression. J Biol Chem. 1990 Mar 25;265(9):5145–5149. [PubMed] [Google Scholar]
  25. Paoletti C., Le Pecq J. B., Dat-Xuong N., Juret P., Garnier H., Amiel J. L., Rouesse J. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137). Recent Results Cancer Res. 1980;74:107–123. doi: 10.1007/978-3-642-81488-4_15. [DOI] [PubMed] [Google Scholar]
  26. Parks J. S., Martin J. A., Johnson F. L., Rudel L. L. Fusion of low density lipoproteins with cholesterol ester-phospholipid microemulsions. Prevention of particle fusion by apolipoprotein A-I. J Biol Chem. 1985 Mar 10;260(5):3155–3163. [PubMed] [Google Scholar]
  27. Patsch J. R., Sailer S., Kostner G., Sandhofer F., Holasek A., Braunsteiner H. Separation of the main lipoprotein density classes from human plasma by rate-zonal ultracentrifugation. J Lipid Res. 1974 Jul;15(4):356–366. [PubMed] [Google Scholar]
  28. Poumay Y., Ronveaux-Dupal M. F. Rapid preparative isolation of concentrated low density lipoproteins and of lipoprotein-deficient serum using vertical rotor gradient ultracentrifugation. J Lipid Res. 1985 Dec;26(12):1476–1480. [PubMed] [Google Scholar]
  29. Ruben R. L., Neubauer R. H. Semiautomated colorimetric assay for in vitro screening of anticancer compounds. Cancer Treat Rep. 1987 Dec;71(12):1141–1149. [PubMed] [Google Scholar]
  30. Rudling M. J., Reihnér E., Einarsson K., Ewerth S., Angelin B. Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. Proc Natl Acad Sci U S A. 1990 May;87(9):3469–3473. doi: 10.1073/pnas.87.9.3469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Samadi-Baboli M., Favre G., Bernadou J., Berg D., Soula G. Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug--LDL complex via the LDL receptor pathway in vitro. Biochem Pharmacol. 1990 Jul 15;40(2):203–212. doi: 10.1016/0006-2952(90)90679-f. [DOI] [PubMed] [Google Scholar]
  32. Samadi-Baboli M., Favre G., Blancy E., Soula G. Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro. Eur J Cancer Clin Oncol. 1989 Feb;25(2):233–241. doi: 10.1016/0277-5379(89)90014-x. [DOI] [PubMed] [Google Scholar]
  33. Shaw J. M., Shaw K. V., Yanovich S., Iwanik M., Futch W. S., Rosowsky A., Schook L. B. Delivery of lipophilic drugs using lipoproteins. Ann N Y Acad Sci. 1987;507:252–271. doi: 10.1111/j.1749-6632.1987.tb45806.x. [DOI] [PubMed] [Google Scholar]
  34. Shepherd J., Bicker S., Lorimer A. R., Packard C. J. Receptor-mediated low density lipoprotein catabolism in man. J Lipid Res. 1979 Nov;20(8):999–1006. [PubMed] [Google Scholar]
  35. Shepherd J., Packard C. J., Bicker S., Lawrie T. D., Morgan H. G. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980 May 29;302(22):1219–1222. doi: 10.1056/NEJM198005293022202. [DOI] [PubMed] [Google Scholar]
  36. Slater H. R., Packard C. J., Shepherd J. Measurement of receptor-independent lipoprotein catabolism using 1,2 cyclohexanedione-modified low density lipoprotein. J Lipid Res. 1982 Jan;23(1):92–96. [PubMed] [Google Scholar]
  37. Vitols S., Angelin B., Ericsson S., Gahrton G., Juliusson G., Masquelier M., Paul C., Peterson C., Rudling M., Söderberg-Reid K. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2598–2602. doi: 10.1073/pnas.87.7.2598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Vitols S., Gahrton G., Björkholm M., Peterson C. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet. 1985 Nov 23;2(8465):1150–1154. doi: 10.1016/s0140-6736(85)92679-0. [DOI] [PubMed] [Google Scholar]
  39. Vitols S., Söderberg-Reid K., Masquelier M., Sjöström B., Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer. 1990 Nov;62(5):724–729. doi: 10.1038/bjc.1990.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. de Smidt P. C., van Berkel T. J. Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res. 1990 Dec 1;50(23):7476–7482. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES